Problem-plagued Ranbaxy Pharmaceuticals Inc. has halted production of generic cholesterol drug Lipitor while it investigates how tiny glass particles got into the ingredients used for dozens of batches of the drug that were ...
Nov 30, 2012
0
0
European regulators have approved a crucial new anticlotting drug, Eliquis, for preventing strokes and dangerous clots in the circulatory system.
Nov 20, 2012
0
0
(HealthDay)—Xeljanz (tofacitinib) has been approved by the U.S. Food and Drug Administration to treat symptoms of rheumatoid arthritis (RA) among people who can't tolerate, or haven't been helped by, the drug methotrexate.
Nov 7, 2012
0
0
(AP)—Advisers to European Union regulators have recommended approval of a new anti-clotting drug for use by adults with a common irregular heart rhythm that boosts risk of strokes or blood clots, drugmakers Bristol-Myers ...
Sep 21, 2012
0
0
An experimental drug that failed to stop mental decline in Alzheimer's patients in the U.S. and Canada also showed some potential benefit in slowing brain plaque, fuller results of two major studies show.
Sep 11, 2012
0
0
Pfizer Inc. and Johnson & Johnson say they are ending development of a once-promising drug designed to treat Alzheimer's disease after the treatment failed in two late-stage clinical trials.
Aug 6, 2012
0
0
(AP) — A closely watched experimental Alzheimer's treatment has failed to slow the disease in one late-stage study, a big disappointment for doctors and patients but not the end of the road for the drug. Pfizer Inc. ...
Jul 23, 2012
0
0
A new study that tracked what Alzheimer's disease and related disorders (ADRD) costs Medicare during three distinct stages of patient care suggests that the government insurer could realize substantial savings through efforts ...
Apr 10, 2012
0
0
Watching Alzheimer's disease steal away the memory, talents and very selves of its victims is hard enough for the people who love them. But a new pill formulated by a respected pharmaceutical company and approved by the Food ...
Mar 23, 2012
0
0
(HealthDay) -- A U.S. Food and Drug Administration advisory panel on Monday will weigh the wisdom of allowing new clinical trials of a class of powerful painkillers for osteoarthritis. The drugs may have worked so well for ...
Mar 12, 2012
0
0
